TG Therapeutics received multiple international drug approvals for its therapy in August 2025.
7 reports, 5 independent
Updated Jun 19
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 7
- Developments
- 2
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TG Therapeutics received multiple international drug approvals for its therapy in August 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BRIUMVI receives US regulatory approval and becomes available.1 source
TG Therapeutics secured approvals from FDA, European Commission, and Swissmedic, among others.1 source
Keep exploring
The entities involved
-
TG Therapeutics
a commercial stage biopharmaceutical company
Nothing else this week.
- FDA
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Hemogenyx Pharmaceuticals Plc submitted an IND application for its HG-CT-1 therapy with the FDA and is building infrastructure for early commercialization in Europe.
- NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Coverage
Newest first; wire copies grouped- insidermonkey.com
- yahoo.com
- GlobeNewswireTG Therapeutics to Participate in the Cantor Global Healthcare Conference Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therap
- ZacksTGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line TG Therapeutics TGTX reported earnings of 17 cents per share for the second quarter of 2025, which substantially missed the Zacks Cons
- BenzingaBriumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 ea
- GlobeNewswireTG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 mil
- GlobeNewswireTG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET NEW YORK, July 30, 2025 (GLOBE NE